Perspective Therapeutics share price logo

Perspective Therapeutics

AMEX: CATX

$0.84

+0.05

(+6.54%)

as on

Perspective Therapeutics Stock Performance

as on November 7, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.80
    $0.91
    downward going graph

    4.76%

    Downside

    8.33%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.78
    $6.16
    downward going graph

    6.98%

    Downside

    633.33%

    Upside

    downward going graph

Perspective Therapeutics share price movements today

Previous Close
$0.79
Open
$0.80
Volume
2.9M
Market Cap
$90.0M
Day's Low - High
$0.80 - $0.91
52 Week Low - High
$0.78 - $6.16

Perspective Therapeutics Historical Returns

1 Month Return
-65.85 %
3 Month Return
-72 %
1 Year Return
-61.64 %
3 Year Return
-68.89 %
5 Year Return
0 %

Perspective Therapeutics Stock Fundamentals & Key Indicators

Check Perspective Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$90.0M

EPS (TTM)

-1.56

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.54

Industry PE ratio

-3.69

PEG Ratio

0.03

EBITDA

-115.1M

Revenue (TTM)

366.0K

Profit Margin

-419.40%

Return On Equity TTM

-41.56%

Perspective Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Perspective Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Perspective Therapeutics image
Perspective Therapeutics
StrongBuy$90.0MNA-0.54-419.40%0.00%
Edwards Lifesciences image
Edwards Lifesciences
StrongBuy$58.1B-13.91%57.7178.13%0.00%
Medtronic image
Medtronic
Buy$134.3B-17.22%24.8966.69%2.73%
Stryker image
Stryker
StrongBuy$129.3B18.00%34.4765.52%1.05%
Abbott Laboratories image
Abbott Laboratories
StrongBuy$199.9B-11.61%40.7157.12%2.22%
See all

Stock Returns calculator for Perspective Therapeutics Stock including INR - Dollar returns

The Perspective Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Perspective Therapeutics investment value today

Current value as on today

₹40,606

Returns

-₹59,394

(-59.39%)

Returns from Perspective Therapeutics Stock

-₹61,644 (-61.64%)

Dollar Impact

₹2,250 (+2.25%)

Analyst Recommendation on Perspective Therapeutics Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Perspective Therapeutics. Average target price of $10.57

Perspective Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Perspective Therapeutics.

What analysts predicted

92.05%UPSIDE

Target Price

$10.57

Current Price

$0.84

Analyzed by

8 Analysts

High

$15

Target

$10.57

Low

$4

Perspective Therapeutics target price $10.57, a slight upside of 92.05% compared to current price of $0.84. According to 8 analysts rating.

Indian Investors' Interest in Perspective Therapeutics Stock

Search interest for Perspective Therapeutics Stock has increased by 204% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:204% versus previous 30 day period

Perspective Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
-
-
0
0
0
-
0
0
Gross Profit
0
0
-
-
0
0
0
-
-1
0
Operating Income
-9
-13
-18
-44
-18
-24
-27
-39
-28
-29
EBITDA
-9
-12
-14
-41
-17
-21
-25
-37
-27
-25
Interest Expense
0
0
0
-
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
1
1
1
Income Before Tax
-9
-11
-15
-42
-15
-21
-25
-38
-26
-26
Income Tax Expense
-
-
-
-2
-
-
-
0
-
0
Net Income
-10
-12
-15
-40
-15
-21
-25
-37
-26
-26
Net Profit Margin
0.00%
0.00%
0.00%
-202.99%
-81.30%
-152.76%
-270.81%
0.00%
-1381.58%
100.00%

Perspective Therapeutics Annual Profit & Loss

All numbers in Millions USD

Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
7
9
10
10
5
1
1
-
Gross Profit
3
5
5
4
2
1
0
-
Operating Income
-5
-3
-3
-7
-9
-40
-66
-113
EBITDA
-5
-3
-3
-7
-8
-39
-64
-100
Interest Expense
-
-
-
-
-
0
0
0
Depreciation
0
0
0
0
0
0
2
3
Income Before Tax
-5
-3
-3
-7
-8
-40
-80
-104
Income Tax Expense
0
0
0
-
-
-2
-2
0
Net Income
-4
-3
-3
-7
-10
-46
-79
-103
Net Profit Margin
41.66%
52.93%
50.94%
42.76%
23.00%
100.00%
-58.60%
0.00%

Perspective Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-12
-11
-15
-40
-18
-21
-25
-37
-26
-26
Operating Cash Flow
13
-8
3
-26
-21
-19
-16
-24
-31
-20
Investing Cash Flow
-47
-3
-29
-138
-5
4
13
28
-109
15
Financing Cash Flow
166
122
0
0
9
0
0
0
164
0
Change in Cash
132
109
-25
-164
-17
-15
-2
3
23
-5

Perspective Therapeutics Annual Cash Flow

All numbers in Millions USD

Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-5
-3
-3
-7
-10
-46
-79
-103
Operating Cash Flow
-5
-3
-2
-7
-10
-36
-18
-82
Investing Cash Flow
0
0
0
0
-28
24
-218
41
Financing Cash Flow
7
0
64
0
0
0
289
10
Change in Cash
2
-2
61
-7
-7
-11
52
-30

Global Institutional Holdings in Perspective Therapeutics

Check out the Institutions with significant holdings in Perspective Therapeutics.

Funds
Holdings
Lantheus Holdings, Inc.
10.13%
Lantheus Alpha Therapy, LLC
9.88%
BlackRock, Inc.
8.32%
Vanguard
4.63%
iShares
4.04%
See all

Perspective Therapeutics News & Key Events

  • img

    Today's Timeline - 06 November

    Fri, 11:04 PM

    -

    Perspective Therapeutics updates VMT01 trial results, showing promising responses in melanoma patients with no serious adverse events reported.

Insights on Perspective Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 43.0K → 81.0K (in $), with an average increase of 24.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Edwards Lifesciences Corp has given 54.2% return, outperforming this stock by 123.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Edwards Lifesciences Corp has given 22.5% return, outperforming this stock by 84.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CATX stock has moved down by -27.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -26.18M → -26.78M (in $), with an average decrease of 2.3% per quarter

About Perspective Therapeutics

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
OrganisationPerspective Therapeutics
Headquarters2401 Elliott Avenue, Seattle, WA, 98121, US
IndustryMedical - Devices
CEOJohan Spoor

Key Management of Perspective Therapeutics

Name

Title

Dr. Michael K. Schultz Ph.D.

Co-Founder & Senior Scientific Advisor

Dr. Paul Lyne Ph.D.

Chief Science Officer

Ms. Annie J. Cheng

Vice President of Investor Relations

Mr. Andrew Bright

Executive Vice President of Brachytherapy

Mr. Johan M. Spoor

CEO & Director

Mr. Joel David Sendek

CFO & Principal Financial Officer

Dr. Markus Puhlmann M.B.A., M.D.

Chief Medical Officer

Mr. Shane Cobb

Executive Vice President of Operations

Mr. Jonathan R. Hunt

Chief Accounting Officer

Mr. Chris Nenno

General Counsel & Corporate Secretary

FAQs

What is Perspective Therapeutics share price today?

Perspective Therapeutics share price today is $0.84 as on at the close of the market. Perspective Therapeutics share today touched a day high of $0.91 and a low of $0.80.

What is the 52 week high and 52 week low for Perspective Therapeutics share?

Perspective Therapeutics share touched a 52 week high of $6.16 on and a 52 week low of $0.78 on . Perspective Therapeutics stock price today i.e. is closed at $0.84,which is 86.36% down from its 52 week high and 7.50% up from its 52 week low.

What is Perspective Therapeutics's market capitalisation today?

Perspective Therapeutics market capitalisation is $0.00T as on .

How to invest in Perspective Therapeutics Stock (CATX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Perspective Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Perspective Therapeutics Stock (CATX) from India?

Indian investors can start investing in Perspective Therapeutics (CATX) shares with as little as ₹93.91000366210938 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.10 in Perspective Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Perspective Therapeutics share’s latest price of $0.84 as on November 7, 2026 at 8:45 am IST, you will get 11.9048 shares of Perspective Therapeutics. Learn more about fractional shares .